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Abstract
We have recently identified that the role of secreted protein acidic and rich in cysteine (SPARC) in amelioration of
peritoneal ovarian carcinomatosis is mediated, at least in part, through mesothelial cell/lysophosphatidic acid–
induced inflammatory response in ovarian cancer cells. The aim of this study was to elucidate the molecular
mechanisms of the interactions between tumor cells and the cellular components of the ovarian cancer peritoneal
microenvironment, specifically, mesothelial cells and macrophages. We found that SPARC not only significantly
reduced macrophage chemoattractant protein-1 production and its macrophage chemotactic effect, but also
attenuated the response of ovarian cancer cells to the mitogenic and proinvasive effects of macrophage chemo-
attractant protein-1 and decreased macrophage-induced cancer cell invasiveness. Overexpression of SPARC in
ovarian cancer cells significantly attenuated macrophage- and mesothelial cell–induced production and activity
of interleukin-6, prostanoids (prostaglandins E2 and 8-isoprostanes) as well as matrix metalloproteinases and
urokinase plasminogen activator. Moreover, the effects of SPARC overexpression in ovarian cancer cells were
mediated, in part, through inhibition of nuclear factor-κB promoter activation. These results indicate, for the first
time, that the effects of tumor SPARC as a negative regulator of ovarian cancer are mediated through decreased
recruitment of macrophages and downregulation of the associated inflammation.
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Introduction
The importance of reactive tumor microenvironment was empha-
sized as early as 1889 by Paget’s “Seed and Soil” explanation of pref-
erential tumor metastasis [1]. In peritoneal ovarian carcinomatosis,
peritoneal mesothelial cells provide soil for shed ovarian cancer cells,
whereas ascitic fluid represents the reactive tumor microenvironment
that provides an efficient exchange of soluble factors among cancer,
mesothelial, and inflammatory cells to support tumor growth and in-
vasion [2]. The positive correlation between the density of tumor-
associated and tumor-infiltrating macrophages (TAM and TIM)
and the poor prognosis of ovarian cancer has long been established
[3,4]. Macrophages are recruited to the ovarian tumors by a tumor-
derived chemotactic factor, macrophage chemoattractant protein-1
(MCP-1) [5], which in turn directly stimulates cancer cell growth
and induces angiogenesis [6–8]. MCP-1, together with other inflam-
matory cytokines and growth factors, is produced by ovarian cancer
cells stimulated by lysophosphatidic acid (LPA), which is constitu-
tively produced by peritoneal mesothelial cells [9,10]. LPA has been
reported to activate macrophages and cancer cells through multiple
pathways that ultimately lead to upregulation of vascular endothe-
lial growth factor (VEGF), urokinase plasminogen activator (uPA),
matrix metalloproteinases (MMPs), interleukin (IL)-6, and prostaglan-
din E (PGEs) [8,11,12]. These high levels of VEGF, proteases, and
PGE2 in turn promote monocyte recruitment and favor their differen-
tiation into macrophages, rather than antigen processing dendritic cells
[6,9,13,14].
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SPARC (secreted protein acidic and rich in cysteine) is a matricel-
lular glycoprotein that has been implicated in modulating tumor-host
interactions. The role of SPARC in the pathogenesis of different tu-
mors appears to be highly contextual and attributed to whether this
protein is produced by tumor or by neighboring stromal cells and to
the concerted effect of the protein on these cells [15–17]. High ex-
pression of SPARC in tumor cells has been correlated with enhanced
tumor growth, metastasis, and poor survival in various malignancies
[18–22]. Stromal, or host-derived SPARC, has been reported to exert
a dual function on tumor growth. A positive effect of stromal SPARC
on the organization of the extracellular matrix (ECM) and inhibition
of angiogenesis has been shown to limit tumor growth [15,23]. Con-
versely, high levels of stromal expression of SPARC in tumor cells
with epigenetic inactivation of Sparc promoter have been positively
correlated with poor prognosis in various cancers [24–28] or may es-
tablish differential interactions with the surrounding stroma by re-
cruiting immune cells and favoring proteolysis of stromal proteins,
resulting in either promotion or regression of tumor growth [29].
The results of in vitro and in vivo studies have identified SPARC as
a novel ovarian cancer suppressor that functions primarily by virtue
of its de-adhesive ability [30] and antiproliferative and proapoptotic
effects [30–32]. It has also been reported that SPARC expression in
ovarian cancer cells is inversely correlated with the degree of malig-
nancy [31–33]. In agreement with these findings, SPARC promoter
has been found to be hypermethylated in human ovarian cancer
cell lines and tissues, leading to loss of its production and secretion
(Socha and Motamed, unpublished data). We have also reported
the ability of SPARC to modulate ovarian cancer cell interaction
with the ECM components, the production and the activity of
specific growth factors, cytokines, proteases, and bioactive lipids
[10,34]. Moreover, we found that in the immunocompetent SP−/−
mice, the enhanced peritoneal ovarian carcinomatosis was concomi-
tant with massive recruitment of macrophages and was positively cor-
related with the augmented levels and biological activity of ascitic
fluid and its constituents, namely, VEGF, MMPs, MCP-1, IL-6,
prostanoids, and bioactive lipids [34]. The latter results suggested
that host SPARC suppresses peritoneal ovarian cancer through a
negative effect on the interplay between ovarian cancer cells, meso-
thelial cells, and macrophages.
To assess the role of tumor SPARC in modulating the ovarian
cancer microenvironment, we used in vitro systems to dissect the
molecular mechanisms of the interactions between human ovarian
cancer cells, mesothelial cells, and macrophages. Our results strongly
indicate that restoration of SPARC expression in ovarian cancer cells
disrupts the interplay between these three key players, resulting in
significantly attenuated macrophage recruitment and expression of
known markers of inflammation.
Materials and Methods
Cell Lines and Reagents
Human ovarian carcinoma cell lines (SKOV3 and OVCAR3) and
human peritoneal mesothelial cell line (Meso301) were obtained and
maintained as described previously [10,30]. Human monocytoid cell
line (U937) was purchased from ATCC (Manassas, VA) and was
maintained in RPMI 1640 containing 10% FBS (Atlanta Biologicals,
Norcross, GA). Bovine and human osteonectin were purchased from
Haematologic Technologies (Essex, VT). Reduced growth factor
Matrigel was from BD Biosciences (Bedford, MA). PGE2 was
from Cayman Inc. (Ann Arbor, MI). Recombinant human MCP-1
was from Peprotech (Rocky Hill, NJ). Rabbit polyclonal antibodies
against MCP-1 were purchased from Chemicon (Temicula, CA).
Unless otherwise stated, all other chemicals and culture media
were purchased from Sigma (St. Louis, MO) and Fisher Scientific
(Fairlawn, NJ).
Adenoviruses and Plasmids
Replication-deficient adenoviruses expressing either SPARC or green
fluorescent protein (GFP) under the control of the cytomegalovirus
promoter were generated as described previously [10]. For preparation
of SPARC plasmid (pSPARC), human SPARC open reading frame
under the control of the cytomegalovirus promoter was cloned into
pcDNA3.1 (Invitrogen, Carlsbad, CA) using the TOPO sites. Plasmids
of nuclear factor (NF)-κB that contained two copies of the wild-type
NF-κB (WT-pNF-κB-Luc) or the mutated NF-κB (Mut-pNF-κB-Luc)
binding sites ligated to luciferase reporters were kindly provided by
Dr. Jinsong Liu (The University of Texas M. D. Anderson Cancer
Center, Houston, TX). uPA promoter plasmid was kindly provided
by Dr. Shuang Huang (Medical College of Georgia, Augusta, GA).
For adenoviral gene transfer, ovarian cancer cell lines were trans-
duced for 24 hours with adenovirus gene encoding GFP (Ad-GFP)
and GFP and SPARC (Ad-GFP-SPARC) in complete growth me-
dium at a multiplicity of infection of 15 to 25 as described previously
[10]. SPARC protein was detected in cell lysates and conditioned
medium of SKOV3 and OVCAR3 ovarian cancer cell lines, after
Ad-GFP-SPARC transduction, but not GFP-transduced controls.
Cells were then serum-starved for 18 to 24 hours before stimulation
with LPA (10 to 50 μM), MCP-1 (1 to 50 ng/ml), PGE2 (0.5 to
20 nM) or use in coculture experiments.
Microinvasion Assays
Invasion assays were performed as described previously [30]. Har-
vested cells were added to the upper chamber of polycarbonate in-
serts (8-μm pore size, Corning Costar, Corning, NY) coated on ice
with Matrigel diluted 1:3 in serum-free medium (SFM). To test the
effect of ovarian cancer cell invasiveness, SKOV3 and OVCAR3 cells,
transduced or not with Ad-GFP and Ad-GFP-SPARC, were seeded
into the upper well of the chamber. To test the effect of macrophages
on ovarian cancer cell invasion, invasion assays were carried out in
the presence of U937 macrophages seeded in the lower chambers.
The concentrations of U937 macrophages used in the present study
recapitulated those reported in patients with ovarian cancer and were
consistent with previously reported in vitro studies [35,36]. Assays
were carried out for 6 hours at 37°C in a 5% CO2 humidified in-
cubator. The migrated cells were counted in six fields after staining
with hemacolor 3 stain, using an inverted microscope equipped with
a DFC 320 digital camera (Leica Microsystems, Wetzlar, Germany)
under 200× magnification. Macrophage chemotaxis assays were per-
formed using 3-μm pore-size polycarbonate inserts (Corning Costar).
Ovarian cancer cells, grown to 90% confluence in 24-well plates,
were transduced with Ad-GFP and Ad-GFP-SPARC as described
earlier and were co-incubated with Meso301 and U937 macrophages
as described in the figure legends. After incubation at 37°C for
90 minutes, the contents of the upper chamber were aspirated,
washed with PBS, and stained with DAPI (Sigma). U937 migration
was assessed by counting the number of cells attached to the lower
surface of the membrane in six high-power fields per well, using a
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fluorescent microscope equipped with a Q-imaging digital camera
(Leica Microsystems).
Cell Proliferation Assay
CellTiter96 kit (Promega) was used according to the manufac-
turer’s instructions. The number of proliferating cells was determined
colorimetrically by measuring the absorbance at 590 nm (A590) of the
dissolved formazan product after the addition of 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H -tetrazolium
(MTS) for 3 hours.
Immunoblotting and Gelatin Zymography
Subconfluent monolayers of ovarian cancer cells, transduced or
not with Ad-GFP and Ad-GFP-SPARC, were grown in six-well plates
and serum-starved in SFM overnight. Cells were then cocultured
with U937 (2 × 106 cells/ml SFM) and added to 0.22-μm transwell
chambers (Corning, Costar) without direct cell-cell contact for
an additional 24 hours. Cell culture conditioned media (CM) were
collected and cleared by centrifugation. Cells in upper and lower
chambers were harvested in lysis buffer (20 mM Tris, pH 7.4,
150 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.5% sodium deoxy-
cholate, 1% NP-40, 1 mM Na3VO4, and 1× protease inhibitor
cocktail mixture). Lysates were cleared by centrifugation at 12,000g
for 20 minutes at 4°C, and protein concentrations were determined
by BCA assay (Pierce). CM were collected and concentrated five-fold
using Centricon centrifugal filters (Millipore, Bedford, MA). CM
equivalent to 200 μg of ovarian cancer cells, and/or U937 cells and
analyzed by gelatin zymography as described previously [30]. Con-
comitantly, cell lysates (50 μg) of SKOV3, OVCAR3, and/or U937
cells were resolved by 10% SDS-PAGE, transferred onto polyvinyli-
dene fluoride membranes (BioRad, Hercules, CA), and probed with
monoclonal antibody against β-tubulin to ensure equal protein load-
ing. Protein detection was carried out using HRP-conjugated sec-
ondary antibodies and a SuperSignal West Dura Chemiluminescence
kit (Pierce).
Luciferase Assays
Ovarian cancer cell lines (5 × 104/well of 24-well plate) were trans-
fected with 0.5 μg of pSPARC, 0.5 μg of pNF-κB-Luc, 0.5 μg of
mutant-pNF-κB-Luc, 1.5 μg of u-PA-Luc promoter, plus 0.2 μg of
reference plasmid β-galactosidase as an internal control (pβgal), using
Lipofectamine 2000 (Invitrogen) for 24 hours, and then starved for an
additional 24 hours. Cells were then stimulated by LPA and PGE2 for
6 hours or cocultured with U937 cells (in 0.22-μm inserts) before lysis
(Glo Lysis Buffer, Promega, Madison, WI). Luciferase activity (Lucif-
erase Assay Solution, Bright Glo, Promega) was measured according to
the manufacturer’s instructions. β-Galactosidase activity (Galacto-Star
System, Applied Biosystems, Bedford, MA) was also measured to nor-
malize the luciferase activity. Transfection efficiency of ovarian cancer
cells ranged between 60% and 70% (data not shown). The concentra-
tion of pSPARC used herein was sufficient to induce SPARC expres-
sion in ovarian cancer cells at levels comparable to that of exogenous
SPARC concentration used herein, as confirmed by Western blot
analysis of SPARC expression in cell lysates and CM (data not shown).
Determination of MCP-1, IL-6, PGE2, and 8-isoprostane
CM of SKOV3, OVCAR3, Meso301, and U937 from the experi-
mental conditions described in the figure legends were collected and
stored at −80°C. Commercial ELISA kits were used to determine the
concentrations of IL-6 and MCP-1 (RayBioTech. Inc., Norcross, GA).
Enzyme immunoassay kits for 8-isoprostane and PGE2 (Cayman Inc.)
were used according to the manufacturer’s instructions.
Determination of uPA Activity
CM from ovarian cancer cells from different experimental con-
ditions described in the figure legends were collected, centrifuged,
stored at −80°C, and assayed within 48 hours. uPA activity was
measured by a colorimetric assay kit (Chemicon), according to the
supplier’s guidelines. The assay is sensitive over a range of 0.05 to
50 units of u-PA activity, which cleaves a chromogenic substrate, a
tripeptide with pNA group, forming a colored product with detect-
able absorbance at 405 nm (A405).
Statistical Analysis
Data were statistically analyzed by Student’s t test and one-way
analysis of variance, using GraphPad Prism version 3.1 (GraphPad
Software, San Diego CA). Differences were considered significant
at P < .05.
Results
Effect of SPARC on Production and Activity of MCP-1 from
Ovarian Cancer Cells Cultured with Mesothelial Cells
Using cytokine arrays, we have previously shown that exogenous
SPARC inhibits basal and LPA induced MCP-1 production by ovar-
ian cancer cells [10]. In vivo, ascitic fluid of SP−/− mice with perito-
neal ovarian carcinomatosis had significantly higher levels of MCP-1
concomitant with increased TAM and TIM [34]. In the present
study, we show significant time-dependent increase of MCP-1 pro-
duction by ovarian cancer cell lines SKOV3 and OVCAR3, after LPA
stimulation (approximately three- and nine-fold increase after 24 and
48 hours, respectively). Exogenous SPARC, as well as adenoviral ex-
pression of SPARC in SKOV3 and OVCAR3 cell lines, significantly
inhibited both basal (54% to 64%) and LPA-induced MCP-1 produc-
tion (54% and 43% inhibition in SKOV3 at 24 and 48 hours, respec-
tively; 59% and 30% inhibition in OVCAR3 at 24 and 48 hours,
respectively (Figure 1, A and B). Coculture of peritoneal mesothelial
cells, Meso301, with ovarian cancer cells further augmented MCP-1
production in a time-dependent manner. The increase was 16- to
21-fold with SKOV3 at 24 and 48 hours, respectively, and 14- to
20-fold with OVCAR3 at 24 and 48 hours, respectively. Overexpres-
sion of SPARC significantly attenuated the augmented MCP-1 pro-
duction in the cocultures by ∼26% to 36% in SKOV3 at 24 and
48 hours, respectively, and 36% to 28% in OVCAR3 at 24 and
48 hours, respectively. At the functional level, monolayers of SKOV3
and OVCAR3 attracted U937 and stimulated migration toward tumor
cells. This chemotactic effect was significantly attenuated in SKOV3
and OVCAR3 cells overexpressing SPARC (47% and 49%, respec-
tively; Figure 1, C and D). To mimic the in vivo human disease in
which the adhesion of ovarian cancer cells to mesothelial cells triggers
the cascade of peritoneal ovarian carcinomatosis, we used a triple-
culture system where ovarian cancer cells, transduced or not with
Ad-SPARC, were seeded onto monolayers of mesothelial cells in the
bottom chamber of the transwells and tested their chemotactic effect
on U937 macrophages placed in the top chamber of the transwells.
In this system, coculture of ovarian cancer-mesothelial cells increased
chemotactic effect on macrophages by five-fold, relative to that exerted
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by ovarian cancer cells alone. It is noteworthy that mesothelial cell
monolayers had a minor chemotactic effect on macrophages. The
chemotactic activity was significantly abrogated (48%) by overexpres-
sion of SPARC in ovarian cancer cells, an inhibitory effect comparable
to that of MCP-1 neutralizing antibody.
SPARC Attenuates the Mitogenic and Proinvasive Effect
of MCP-1 on Ovarian Cancer Cells
MCP-1 has been reported not only to attract macrophages and
inflammatory cells, but also to promote tumorigenesis through its
proliferative and proinvasive effect on a variety of cancer cells as well
as endothelial cells [15,16,37–40]. Herein, we report that MCP-1
exerts a concentration-dependent stimulatory effect on SKOV3 and
OVCAR3 cell proliferation, an effect that was observed at a con-
centration range of 10 to 50 ng/ml (Figure 2, A and B). Similar
concentrations of MCP-1 also significantly stimulated SKOV3 and
OVCAR3 cell invasiveness (Figure 2, C and D). Overexpression
of SPARC in ovarian cancer cells abrogated their responses to the
mitogenic (17% to 23% and 15% to 27% inhibition for SKOV3
and OVCAR3, respectively) and the proinvasive (15% to 28% and
30% to 43% inhibition for SKOV3 and OVCAR3, respectively)
effects of MCP-1 at all the tested concentrations. These data indi-
cate that MCP-1 secretion by ovarian cancer cells is augmented on
LPA stimulation and in cocultures with peritoneal mesothelial cells.
MCP-1 not only mediated ovarian cancer cell–induced macrophage
chemotaxis, but also exerted a potent mitogenic and a less pro-
nounced proinvasive effect on ovarian cancer cells themselves. Over-
expression of SPARC in ovarian cancer cells attenuated MCP-1
Figure 1. Effect of SPARC on production and activity of MCP-1 in ovarian cancer cells. Confluent monolayers (∼1 × 106 cells, serum-
starved overnight) of wild type (WT), SKOV3, and OVCAR3, were stimulated with 50 μM LPA for 24 hours in the presence and absence
of SPARC (10 μg/ml). Similarly, adenovirus-transduced SKOV3 and OVCAR3 were stimulated with 50 μM LPA for 24 to 48 hours. Alter-
natively, adenovirus-transduced SKOV3 and OVCAR3 were seeded onto confluent monolayers or cocultured with Meso301 for 24 to
48 hours. MCP-1 protein secreted in the CM of SKOV3 (A) and OVCAR3 (B) was determined by ELISA. Controls included cells that
were not stimulated (NS) with LPA. *P < .05, compared to matched nonstimulated or Ad-GFP condition. #P < .05, compared to non-
stimulated WT or Ad-GFP cells. Results shown are mean ± SEM of a representative of three independent experiments, each performed
in duplicate. Overexpression of SPARC in SKOV3 and OVCAR3 abrogated MCP-1–mediated chemotaxis of U937 macrophages. Twenty-
four-hour–transduced SKOV3 (C), and OVCAR3 (D) cells (2 × 105 cells per 600 μl SFM per well) were grown to confluence in 24-well
plates or were seeded onto confluent monolayers of Meso301. U937 macrophages (1 × 105 cells per 100 μl SFM) were added to the
top chamber of the transwells. In some experiments, neutralizing anti–MCP-1 antibody (MCP-1 Ab, 25 μg/ml) was included in Ad-GFP–
transduced ovarian cancer cell-Meso301 cocultures, Results shown are mean ± SEM of a representative of three independent experi-
ments, each performed in triplicate. *P < .05, compared to nonstimulated (NS) or Ad-GFP–transduced cells. **P < .05, compared to
cocultures of Meso301 and Ad-GFP–transduced ovarian cancer cells.
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production and resulted in a partial, although significant, inhibition
of its biological activity.
SPARC Suppresses Macrophage-Induced Ovarian Cancer
Cell Invasion
In patients with ovarian cancer, tumor burden has been positively
correlated with ascitic fluid macrophage content. TIM and TAM
have been reported to enhance tumor dissemination by increasing
tumor cell adhesion molecules on the peritoneal mesothelium [41].
TAM purified from ascites of patients with ovarian cancer revealed
the presence of a macrophage-derived factor that promoted tumor
neovascularization, growth, and metastasis. Ovarian tumor macro-
phage products include growth, angiogenic, and survival factors such
as IL-6 and VEGF [41]. In vitro, coculture of macrophages with
ovarian tumor cells resulted in the induction of a tumor-promoting
phenotype [35,36]. Recently, in an in vivo study using immuno-
compromised as well as immunocompetent animal models, an overall
protumor effect of macrophages in ovarian cancer dissemination has
been reported [42]. Interestingly, using a syngeneic ovarian cancer
model in SP−/− mice, we have recently reported that TAM and TIM
were positively correlated with tumor burden, ascitic fluid volume, and
the levels of IL-6, VEGF, and MMPs [34]. These observations led us
to investigate the effect of tumor-derived SPARC on the interaction of
macrophages with ovarian cancer cells. We found that cocultures of
U937 macrophages with tumor cells significantly increased the inva-
siveness of SKOV3 (∼50%) and OVCAR3 (approximately three-fold)
cell lines, over single-cell cultures (Figure 3A). Restoring SPARC expres-
sion in ovarian cancer cell lines significantly abrogated macrophage-
induced invasiveness (48% to 50%).
We next sought to identify the soluble factors implicated in
macrophage-induced tumor cell invasiveness and the effect of
SPARC on these factors. We found that in cocultures of ovarian can-
cer cells and macrophages, IL-6 levels were significantly augmented
over the basal secretion by SKOV3 (17-fold), OVCAR3 (17.6-fold),
or U937 (25- to 28-fold). Restoring SPARC expression in ovarian
cancer cells significantly decreased IL-6 production in cocultures
Figure 2. Effect of SPARC on regulation of mitogenic and proinvasive functions of MCP-1 in ovarian cancer cells. Proliferation of SKOV3
(A) and OVCAR3 (B) transduced or not with Ad-GFP and Ad-GFP-SPARC, in response to indicated concentrations of MCP-1, was as-
sessed by MTS assays. Results shown are expressed as the mean ± SEM of three independent experiments performed in quadrupli-
cate. *P < .05, compared to NS cells. #P < .05, compared to the matched untransduced WT or Ad-GFP–transduced cells. The
proinvasive activity of MCP-1 was assessed by Matrigel-invasion assays. SKOV3 (C) and OVCAR3 (D), transduced or not with Ad-GFP
and Ad-GFP-SPARC (1 × 105 cells per 100 μl SFM), were added to the upper chamber of Matrigel-coated inserts in the presence and
absence of the indicated concentrations of MCP-1. In some experiments, cells were pretreated with MCP-1 antibody (Ab) or its isotype
control (50 μg/ml) for 30 minutes before stimulation, as described earlier. The bottom chambers contained complete growth medium.
Results shown are the mean ± SEM of three independent experiments performed in triplicate. *P < .05, compared to control NS cells.
#P < .01, compared to matched WT or Ad-GFP–transduced cells.
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with SKOV3 and OVCAR3 by 39% and 55%, respectively (Fig-
ure 3B). Interestingly, incorporating Meso301 in the triple cultures
resulted in a significant increase in IL-6 production (∼2.5-fold over
U937-SKOV3 and U937-OVCAR3 cocultures). This increase was
attenuated by restoring SPARC expression in SKOV3 and OVCAR3
cells (44% and 28%, respectively). Neither exogenous SPARC nor
overexpression of SPARC in U937 had any effect on their IL-6 levels.
We have recently reported that SPARC partially, but significantly,
attenuated the mitogenic and motogenic effects of IL-6 on human
ovarian cancer cells in vitro as well as in vivo, in a syngeneic murine
ovarian cancer model [10,34].
Coculture of Ovarian Cancer Cells with Mesothelial
Cells and Macrophages Induces Increased MMP
Secretion by Macrophages
Coculture of macrophages with tumor cells has been shown to in-
duce MMP expression in both macrophages and tumor cells, as well
as increased MMP activity in the coculture supernatants [43]. Fur-
thermore, MMP-2 and -9 have been colocalized with TAM in lung
cancer specimens as well as in cocultures [21]. We have recently
reported that the augmented proteolytic activity of ascitic fluid
as well as the transcriptional and posttranscriptional upregulation
of MMP-2 and -9 in tumor-bearing SP−/− mice was concomitant
with a marked increase in macrophage infiltration in tumors and
the ascitic fluid of the SP−/− compared with the SP+/+ counterparts
[30,34]. We next determined which cells contributed to MMP pro-
duction and the possible mechanisms of regulation by SPARC.
Whereas CM of OVCAR3 had barely detectable basal activity of
pro- and active MMP-9, that of SKOV3 showed a significant ac-
tivity of pro- and active MMP-9 as well as pro-MMP-2. There
was no difference in the enzymatic activity of these gelatinases be-
tween WT and Ad-GFP–transduced ovarian cancer cells. Ad-GFP-
SPARC transduction decreased levels of pro- and active MMP-9 in
OVCAR3, whereas in SKOV3, it decreased both MMP-2 and
Figure 3. Regulation of macrophage-induced ovarian cancer cell invasiveness by SPARC. SKOV3 and OVCAR3 cells, transduced or not
with Ad-GFP and Ad-GFP-SPARC, were seeded into the upper chambers of Matrigel-coated inserts (1 × 105 cells per 100 μl SFM per
well). U937 macrophages (2 × 106 cells per 600 μl SFM) were seeded in the lower chambers. The number of invading cells was de-
termined as reported earlier (A). Results shown are the mean ± SEM of three independent experiments performed in triplicate. *P< .05,
compared to control SKOV3 and OVCAR3 cells in single-cell cultures, using complete growth medium (CGM) in the bottom chamber.
IL-6 production in the CM of U937-ovarian cancer cocultures or triple cultures with Meso301 cells were determined by ELISA (B). Cells
were treated as described in the legend of Figure 1, A and B, and 24-hour CM were used for IL-6 determination by ELISA. Bars represent
the mean ± SEM of one of three independent experiments, each performed in duplicates. *P < .05, compared to matched WT or
Ad-GFP. **P < .05, compared to double cultures in the absence of mesothelial cells.
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MMP-9 activity without affecting either pro-MMP-2 or MMP-9
levels (Figure 4A).
LPA stimulation significantly increased the levels of active MMP-9
in OVCAR3 and that of pro- and active MMP-9 in SKOV3.
Ad-GFP-SPARC transduction markedly decreased LPA-induced
MMP-9 activity in both OVCAR3 and SKOV3. Interestingly, co-
culture of either ovarian cancer cell line with Meso301 resulted in
the most significant increase in the levels and activity of the pro-
and active forms of MMP-2 and MMP-9 (Figure 4A). To determine
the contribution of macrophages to production of MMPs, we found
that the CM of U937 exhibited the highest basal activity level of
MMP-2 and MMP-9 compared with either SKOV3 or OVCAR3
(Figure 4B). LPA significantly increased MMP-2 and MMP-9 activ-
ity. Exogenous SPARC (20 μg/ml) markedly decreased LPA-induced
activity of both MMP-2 and MMP-9. Coculture of U937 with either
SKOV3 or OVCAR3 resulted in a marked increase in the levels of
Figure 4. Differential effect of SPARC on the proteolytic activity of ovarian cancer cells and macrophages. The gelatinolytic activity of
MMP-2 and -9 in CM of SKOV3 and OVCAR3 cells, transduced or not with Ad-GFP-SPARC, was determined after LPA stimulation or
coculture with Meso301 monolayers (A). The gelatinolytic activity of MMP-2 and -9 in CM of U937 stimulated with LPA (50 μM)
or cocultured with SKOV3 and OVCAR3, with and without Meso301 (B). Exogenous SPARC (20 μl) was included in some experiments.
SKOV3 (C) and OVCAR3 (D) cells were cotransfected with a uPA promoter luciferase reporter plasmid and a mammalian expression
vector encoding SPARC (pSPARC) and relative luciferase units (RLU) was determined after LPA (10 to 50 μM) stimulation for 6 hours or
after coculture with U937 cells. Bars are the mean ± SEM of three independent experiments performed in triplicate. *P< .05, compared
to NS controls. **P < .05, compared to matched experimental condition without pSPARC cotransfection. uPA activity in CM of con-
fluent monolayers serum-starved overnight (∼1 × 106 cells) of SKOV3 (E) and OVCAR3 (F) were measured in WT cells stimulated for
24 hours with LPA (50 μM) in the presence and absence of SPARC (10 μg/ml). Similarly, adenovirus-transduced SKOV3 and OVCAR3
were stimulated with LPA. Alternatively, adenovirus-transduced SKOV3 and OVCAR3 were either cocultured with Meso301 monolayers,
U937 macrophages (added in 0.22-μm transwell inserts), or in triple-culture systems. uPA activity is expressed as fold change from
control WT SKOV3 or OVCAR3 that were not stimulated (NS), assigned a value of 1. Results shown are mean ± SEM of a representative
of three independent experiments, each performed in duplicate. *P < .05, compared to nonstimulated WT or Ad-GFP cells. **P < .05,
compared to matched WT or Ad-GFP condition. #P < .05, compared to coculture of ovarian cancer cells with either Meso301 or U937 in
two-cell culture systems.
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pro- and active MMP-9 and MMP-2. Both were significantly atten-
uated by Ad-SPARC transduction of ovarian cancer cells. As antici-
pated, CM from triple cultures including Meso301 cells exhibited
a pronounced increase in the levels and activity of pro- and active
MMP-2 and MMP-9. The inhibitory effect of Ad-SPARC trans-
duction was more pronounced on MMP-9 levels and activity than
on MMP-2 in SKOV3 and OVCAR3. It is noteworthy that CM
from Meso301 alone had undetectable gelatinolytic activity (data
not shown). These results indicate that the proteolytic activity
of MMP-2 and MMP-9 in ovarian cancer is attributed not only to
the constitutive production by ovarian cancer cells and macro-
phages, but more importantly, to their activation by interaction of
ovarian cancer cells with mesothelial cells and macrophages.
Although these interactions differentially regulated the levels and
activity of both MMP-2 and MMP-9 in SKOV3, OVCAR3, and
U937 macrophages, changes in MMP-9 were more pronounced both
in response to the stimulatory effects of LPA in cocultures and to
the inhibitory effect of SPARC adenoviral gene transfer. Further-
more, the pattern of induction of MMP-2 and MMP-9 activity
and their inhibition by Ad-SPARC observed in the present study sug-
gest a possible role for SPARC in downregulation of the activity levels
of these MMPs.
SPARC Attenuates LPA-Induced uPA Activity in Ovarian
Cancer Cells
uPA is a serine proteinase that catalyzes the conversion of plas-
minogen to plasmin, a broad-spectrum serine protease that not only
degrades numerous components of the ECM, but has also been
implicated in activation of other MMPs as well as uPA itself. High
levels of uPA have been associated with MMP-2 and -9 in the ascitic
fluids and tumors of patients with stages I to IV ovarian cancer and
were correlated with the increased invasiveness of ovarian cancer cells
[14,44]. Furthermore, the expression of uPA in ovarian cancer has
been shown to be upregulated by a myriad of stimuli, of which
LPA is the most putative [45]. Therefore, we determined whether
SPARC plays a role in regulation of uPA expression and activity.
First, we studied the effect of SPARC on uPA promoter activity.
We found that transient transfection of ovarian cancer cells with
pSPARC significantly decreased the basal activity of uPA promoter
in both SKOV3 (42%, Figure 4C ) and OVCAR3 (∼43%, Fig-
ure 4D). LPA stimulation of uPA promoter activity was concentra-
tion dependent in both SKOV3 (6% to 115%) and OVCAR3 (38%
to 325%). Cotransfection with pSPARC significantly attenuated
LPA-induced uPA promoter activity in SKOV3 (40% to 43% in-
hibition) and OVCAR3 (51% to 63%). Interestingly, coculture of
either SKOV3 or OVCAR3 cells with U937 macrophages resulted
in significant stimulation of uPA promoter activity (69% and 170%
increase in SKOV3 and OVCAR3, respectively); an increase that was
partially, although significantly, attenuated by pSPARC cotransfection
(26% and 36% inhibition in SKOV3 and OVCAR3, respectively).
Using a colorimetric assay for uPA activity analysis in CM, we found
that the constitutive uPA activity in CM of SKOV3 (Figure 4E) and
OVCAR3 (Figure 4F ) was partially but significantly attenuated by
either exogenous SPARC or Ad-SPARC transduction (40% and
29% in SKOV3 and OVCAR3, respectively). Exogenous SPARC sig-
nificantly inhibited LPA-induced uPA activity in SKOV3 (76%) and
OVCAR3 (36%). Although LPA induced a 4- to 4.5-fold increase in
uPA activity in untransduced WT and Ad-GFP–transduced SKOV3
and OVCAR3 controls, respectively, the inhibitory effect of Ad-
SPARC transduction was significant (38% and 28% inhibition, for
SKOV3 and OVCAR3, respectively), albeit less pronounced than that
of exogenous SPARC for both cell lines. Coculture of either SKOV3
or OVCAR3 with Meso301 resulted in an increase in uPA activity in
their CM, comparable to that of LPA stimulation. Ad-SPARC trans-
duction resulted in a modest yet significant decrease in uPA activity by
∼160% and ∼60% in SKOV3 and OVCAR3, respectively. Further-
more, cocultures of U937 with either SKOV3 or OVCAR3 increased
uPA activity in CM by 1.7- to 2-fold that was attenuated by Ad-
SPARC transduction of SKOV3 (∼110%) and OVCAR3 (∼70%).
Moreover, triple cultures, including Meso301 with ovarian cancer cells
and U937 macrophages, resulted in a significantly augmented uPA
activity in their CM (6.2- and 5.6-fold for SKOV3 and OVCAR3,
respectively) and was shown to be attenuated by Ad-SPARC transduc-
tion in SKOV3 (∼160%) and OVCAR3 (∼120%).
SPARC Attenuates PGE2 Production and Activity
in Culture Supernatants of Ovarian Cancer Cells
with Mesothelial Cells and/or Macrophages
PGE2, the most common prostanoid, is involved in tumor pro-
gression by inducing angiogenesis, invasion, and metastasis in several
solid tumors [11,46,47]. In vitro PGE2 treatment stimulated prolif-
eration of ovarian cancer cells and reduced apoptosis [48] as well as
inhibition of immune surveillance [13]. PGE2 participates in these
complex mechanisms by stimulating VEGF secretion [49], cell mi-
gration, and expression and activation of MMPs [11]. The increase
in eicosanoids, including PGE2 observed in patients with cancer,
has been variably attributed to active secretion by tumor tissues,
the products of coagulation and inflammation, and active secretion
by macrophages [11,49]. Having shown the different effects of
SPARC in modulating tumor cell interactions with mesothelial cells
and macrophages, as well as LPA stimulation, we sought to deter-
mine whether SPARC exerts an effect on prostanoids as well. We
found that the baseline production of PGE2 by serum-starved
SKOV3 (∼7 pg/ml) and OVCAR3 (∼5 pg/ml) was decreased by both
exogenous and Ad-SPARC transduction by up to 30% to 50%,
respectively (Figure 5, A and B). LPA stimulation of SKOV3 and
OVCAR resulted in ∼14-fold increase in PGE2 production, which
was suppressed 40% to 55% by exogenous or Ad-SPARC transduc-
tion of either cell line, respectively. PGE2 production was augmented
to 22- to 30-fold by coculture of Meso301 with SKOV3 and
OVCAR3, respectively. Transduction of SKOV3 and OVCAR3 with
Ad-SPARC resulted in significant (40%) decrease in PGE2 produc-
tion. Similar augmentation of PGE2 production was observed in
cocultures of SKOV3 or OVCAR3 with U937 macrophages. Ad-
SPARC transduction resulted in a significant decrease in PGE2
production in cocultures involving SKOV3 (50%), but not with
OVCAR3 (14%). Further amplification of PGE2 production (80- to
100-fold) was observed in triple cultures and was significantly attenu-
ated by Ad-SPARC transduction of SKOV3 but not of OVCAR3.
Next, we tested whether SPARC decreases the responsiveness of ovarian
cancer cells to the mitogenic and proinvasive effects of PGE2. We
found that PGE2-stimulated proliferation of SKOV3 (Figure 5C )
and OVCAR3 (Figure 5D) was concentration dependent up to
10 nM. Ad-SPARC transduction partially attenuated the response of
SKOV3 and OVCAR3 to PGE2-induced proliferation by 28% to
38% in SKOV3 and 32% to 49% in OVCAR3, respectively. Simi-
larly, the proinvasive effect of PGE2 on SKOV3 (Figure 5E ) and
OVCAR3 (Figure 5F) was concentration dependent and was partially
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but significantly inhibited by Ad-SPARC (12% to 35% and 20% to
45% in SKOV3 and OVCAR3, respectively).
Effect of SPARC on the Production of Reactive Oxygen Species
Isoprostanes are prostaglandin isomers produced from the per-
oxidation of cell membrane phospholipids, and have been used as
an indirect measure of oxidative stress. The chronic presence of the
proliferating tumor cells and thus chronic activation of inflamma-
tory cells, results in increased production of reactive oxygen species
(ROS). This is supported by the observation that patients with can-
cer showed signs of extensive activation of inflammatory cells, with
massive elevation of plasma levels of 8-isoprostane [50]. Further-
more, tumor cells activate inflammatory cells through production
of cytokines. IL-6 is one of the candidate cytokines that are elevated
in the serum of patients with cancer, and stimulate the oxidative
burst and ROS generation [7,51]. Moreover, 8-isoprostane has re-
cently been linked to UV-induced inflammation and lipid peroxida-
tion in basal cell and squamous cell carcinomas of the skin as well as
in melanoma [45]. We have recently shown that the increased pro-
duction of 8-isoprostane in murine peritoneal ovarian carcinomatosis
was positively correlated with enhanced tumor growth, increased
TAM and TIM, as well as augmented levels of mitogenic and inflam-
matory cytokines and growth factors in SP−/− mice compared with
SP+/+ counterparts [34]. In the present study, we show that the basal
levels of ROS production, as measured by 8-isoprostane in serum-
starved SKOV3 (52 pg/ml) and OVCAR3 (38 pg/ml), was decreased
Figure 5. SPARC attenuates PGE2 production and activity in cocultures of ovarian cancer cells with mesothelial cells and/or macro-
phages. SKOV3 (A) and OVCAR3 (B) cells were treated as described in Figure 4, A and B, and PGE2 level was determined in the CM
by enzyme immunoassay. *P < .05, compared to nonstimulated WT or Ad-GFP cells. **P < .05, compared to matched WT or Ad-GFP
condition. #P < .05, compared to cocultures of ovarian cancer cells with either Meso301 or U937 in a two-cell culture system. Pro-
liferation of SKOV3 (C) and OVCAR3 (D) cells, transduced or not with Ad-GFP and Ad-GFP-SPARC, in response to the indicated concen-
trations of PGE2, was assessed by MTS assays. Results shown are expressed as the mean ± SEM of three independent experiments
performed in quadruplicate. *P < .05, compared to the matched WT or Ad-GFP transduction. **P < .05, compared to NS control cells.
The proinvasive activity of PGE2 on SKOV3 (E) and OVCAR3 (F) was determined in Matrigel invasion assays. Cells were treated as
described in Figure 2, C and D, and were treated with the indicated concentrations of PGE2. Results shown are the mean ± SEM
of three independent experiments performed in triplicates. **P < .05, compared to matched WT or Ad-GFP–transduced cells. *P <
.05, compared to NS controls.
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by both exogenous SPARC and Ad-SPARC by 70% to 90%,
respectively (Figure 6, A and B). LPA stimulation of SKOV3 and
OVCAR resulted in an increase (∼2.2- to 2.5-fold, respectively) in
8-isoprostane production, which was suppressed up to 26% to
55% by addition of exogenous SPARC or Ad-SPARC transduction
of either cell line, respectively. The suppression of LPA-induced
8-isoprostane production by SPARC was significant only with
OVACR3 cells, but not with SKOV3 cells. The production of
8-isoprostane was amplified to approximately seven- and four-fold
in cocultures of Meso301 with SKOV3 and OVCAR, respectively.
Transduction of SKOV3 and OVCAR3 with Ad-SPARC resulted
in a significant inhibition of ROS by 48% and 74% in cocultures
of Meso301 with SKOV3 and OVCAR3, respectively. Similarly,
cocultures of SKOV3 or OVCAR3 with U937 macrophages resulted
in amplification of 8-isoprostane production that was significantly
decreased (∼50%) by Ad-SPARC transduction of either ovarian
cancer cell line. Further amplification of 8-isoprostane production
(five- to eight-fold) was observed in triple cultures and was signifi-
cantly attenuated by Ad-SPARC transduction of SKOV3 (45%)
and OVCAR3 (52%).
Activation of NF-κB Promoter
The activation of NF-κB, which is seen in most cancer cells, plays
a key role in tumor initiation, progression, metastasis, and chemo-
resistance by mediating the production of a large variety of pro-
inflammatory cytokines, chemokines, growth factors, collagenases,
and antiapoptotic proteins. Analysis of the molecular basis of the
TAM phenotype has identified NF-κB as the master regulator of
macrophage-tumor cell interactions [35,36,52]. In vitro data have
also linked ROS to activation of NF-κB, which, in turn, regulates
transcription of many proinflammatory mediators [53]. In the pres-
ent study, we tested whether the modulation of macrophage-tumor
cell interaction by SPARC is mediated through interfering with
NF-κB activation. We found that cocultures of U937 macrophages
with SKOV3 (Figure 7A) and OVCAR3 cells (Figure 7B) resulted in
a significant increase in NF-κB activation compared with nonco-
cultured ovarian cancer cells (∼5- and 3.5-fold increase in SKOV3
and OVCAR3, respectively). Transient transfection of ovarian cancer
cells with pSPARC attenuated the macrophage-induced NF-κB ac-
tivation by 40% and 53% in SKOV3 and OVACR3, respectively.
LPA-induced NF-κB activation (40% to 50%) in both SKOV3
(Figure 7C ) and OVCAR3 (Figure 7D). Cotransfection of SKOV3
and OVCAR3 with pSPARC attenuated LPA-induced NF-κB acti-
vation by ∼50% in both cell lines. Furthermore, we also found that
PGE2 treatment of SKOV3 (Figure 7E ) and OVCAR3 (Figure 7F ),
resulted in a concentration-dependent NF-κB activation (approxi-
mately three-fold) up to 5 nM. Cotransfection of ovarian cancer cells
with pSPARC resulted in a significant (30% to 50%) attenuation of
PGE2-induced NF-κB activation in both cell lines. It is noteworthy
that transient transfection of either SKOV3 or OVCAR3 with
pSPARC significantly decreased (40%) their basal activity of NF-κB.
Discussion
Recent studies have elucidated the importance of the fluid micro-
environment of malignant ascites in influencing the malignancy of
ovarian tumors. The formation and composition of ascitic fluid
Figure 6. SPARC attenuates 8-isoprostane production in culture supernatants of ovarian cancer cells with mesothelial cells and/or
macrophages. SKOV3 (A) and OVCAR3 (B) were treated as described in Figure 4, A and B, and the level of 8-isoprostane was determined
in the CM by enzyme immunoassay. *P < .05, compared to nonstimulated WT or Ad-GFP cells. **P < .05, compared to matched WT or
Ad-GFP condition. #P < .05, compared to coculture of ovarian cancer cells with either Meso301 or U937 in two-cell culture systems.
§P < .05, between cocultures of OVCAR3-Meso and OVCAR3-U937.
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not only represent the outcome of the tumor cell interactions with
mesothelial and inflammatory cells, but also allow the efficient ex-
change of soluble factors among these cells, sustaining tumor cell
growth and invasion [2]. Our recent in vivo approach allowed us
to determine the effect of host SPARC in negative regulation of in-
flammation in a syngeneic model of murine ovarian cancer [30,34].
We found that ovarian tumor dissemination in the SP−/− peritoneum
was accompanied by massive macrophage infiltration together with
increased inflammatory mediators, which exerted mitogenic and
motogenic effects on murine ovarian cancer cells and enhanced the
angiogenic and proteolytic activity of the ascitic fluid. The current
study was designed to determine whether tumor-derived SPARC
affects the inflammatory responses that accompany the dissemina-
tion of ovarian tumors. Herein, we analyzed the effects of restoring
SPARC expression in low- and high-metastatic ovarian cancer cell
lines devoid of SPARC on their interaction with mesothelial cells
and macrophages, the major cellular constituents of ovarian cancer
microenvironment. Our results indicated that SPARC reexpression
in ovarian cancer cells by adenovirus not only decreased their LPA-
or mesothelial cell–induced macrophage chemotaxis, but also de-
sensitized them to the mitogenic and motogenic effects of MCP-1.
The important role of macrophages in ovarian cancer cell invasion,
proliferation, survival, and metastasis was attributed to the upregu-
lation of VEGF and other proangiogenic and proteolytic factors in
Figure 7. Effect of SPARC on NF-κB promoter activity. SKOV3 (A) and OVCAR3 (B) were transfected with pSPARC and either pNF-κB-
Luc-WT or pNF-κB-Luc-Mut and were cocultured with U937 without direct cell-cell contact. Bars represent the mean ± SEM of the
relative luciferase activity, corrected to β-gal activity, of three independent experiments performed in triplicates. *P < .05, compared
to SKOV3 and OVCAR3 in single-cell culture. **P < .05, between cocultures without pSPARC transfection of ovarian cancer cells.
SKOV3 (C) and OVCAR3 (D) were cotransfected as described earlier and stimulated with the indicated concentrations of LPA. Bars
represent the mean ± SEM of relative luciferase activity, corrected to β-gal activity, of three independent experiments performed in
triplicate. *P < .05, compared to matched NS or LPA-stimulated cells without pSPARC cotransfection. ***P < .05, compared to NS,
and between each concentration of LPA stimulation. Similarly cotransfected SKOV3 (E) and OVCAR3 (F) cells were stimulated with the
indicated concentrations of PGE2. Bars represent the mean ± SEM of three independent experiments performed in triplicate. *P < .05,
compared to matched NS or PGE2-stimulated cells without pSPARC cotransfection. **P< .05, compared to NS and between the tested
concentrations of PGE2.
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response to hypoxia, with positive correlation with TIMs in ovarian
cancer spheroids [35,42,43]. In the present study, we found that co-
cultures of macrophages with ovarian cancer cells significantly up-
regulated the expression of IL-6. This effect was further augmented in
triple cultures, where ovarian cancer cells were overlaid onto mono-
layers of mesothelial cells. We have previously reported the effect of
Ad-SPARC gene transfer in ovarian cancer cells on their response to
the proinvasive as well as the mitogenic and survival signaling path-
ways induced by IL-6 [10]. There is a large body of experimental
and clinical evidence that the proteolytic activity of ovarian cancer
ascites is mediated through MMPs (-2 and -9) and uPA, which is
induced by TAMs either directly or through overproduction of LPA,
IL-6, and PGE2 [2,45,46,54,55]. Our results in the present study
are consistent with those of the aforementioned reports. Furthermore,
we found that reexpression of SPARC in ovarian cancer cells by
adenovirus vectors markedly decreased the LPA-, mesothelial cell-,
and macrophage-induced MMPs (-2 and -9) as well as the uPA activ-
ity. Consistent with these reports, PGE2 and 8-isoprostane production
were significantly downregulated by Ad-SPARC. Moreover, we
found that the effects of SPARC were mediated through decreased ac-
tivation of the transcription factor NF-κB in ovarian cancer cells. It has
been reported that exposure to malignant exudates or cocultures with
activated macrophages enhances cancer cell proliferation and invasive-
ness. These events are all actively regulated by LPA and PGE2 [43,56].
Taken together, our results indicate that ectopic expression of
SPARC in ovarian cancer cells negatively regulates the inflammatory
responses elicited on interaction of tumor cells with mesothelial cells
and/or macrophages. Therefore, it is plausible to suggest that restor-
ing SPARC expression in ovarian tumors may not only impede the
formation of ascites, but also decreases responsiveness of the ovarian
cancer cells to the mitogenic and proinvasive stimuli in the ascitic
fluid milieu.
SPARC-based gene or protein therapy has been shown to be a
promising novel approach in regression of xenografted neuroblas-
toma as well as in chemo- and radiation therapy–refractory colorectal
cancers [57,58]. Because ovarian cancer is confined mostly to the
peritoneal cavity, it lends itself to intraperitoneal chemotherapy,
which has fewer adverse effects compared with intravenous therapy
[59–61]. Given our recent findings and the established antiprolifera-
tive, proapoptotic, and antimetastatic properties of SPARC in ovarian
cancer, intraperitoneal delivery of SPARC by gene/protein therapy
approaches in combination with traditional chemotherapy regimens
could prove to be a novel, efficacious mode of therapy for late-stage
peritoneal ovarian carcinomatosis.
Acknowledgments
We sincerely thank Simone Kennard and Dr. Brenda Lilly for their
technical help with luciferase assays. We also thank Dr. Neil Desai,
Dr. Vuong Trieu, and Shihe Hou for helpful suggestions and critical
reading of the manuscript.
References
[1] Paget S (1889). The distribution of secondary growths in cancers of the breast.
Lancet 133, 571–573.
[2] Kassis J, Klominek J, and Kohn EC (2005). Tumor microenvironment: what
can effusions teach us? Diagn Cytopathol 33, 316–319.
[3] Mantovani A, Bottazzi B, Sozzani S, Peri G, Allavena P, Dong QG, Vecchi A,
and Colotta F (1995). Cytokine regulation of monocyte recruitment. Arch
Immunol Ther Exp (Warsz) 43, 149–152.
[4] Freedman RS, Deavers M, Liu J, and Wang E (2004). Peritoneal inflammation—
a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2, 23.
[5] Mantovani A, Bottazzi B, Colotta F, Sozzani S, and Ruco L (1992). The origin
and function of tumor-associated macrophages. Immunol Today 13, 265–270.
[6] Balkwill F (2003). Chemokine biology in cancer. Semin Immunol 15, 49–55.
[7] Mantovani A, Schioppa T, Biswas SK, Marchesi F, Allavena P, and Sica A
(2003). Tumor-associated macrophages and dendritic cells as prototypic type
II polarized myeloid populations. Tumori 89, 459–468.
[8] Fang XJ, Schummer M, Mao ML, Yu SX, Tabassam FH, Swaby R, Hasegawa Y,
Tanyi JL, LaPushin R, Eder A, et al. (2002). Lysophosphatidic acid is a bioactive
mediator in ovarian cancer. Biochim Biophys Acta 1582, 257–264.
[9] Lewis CE and Pollard JW (2006). Distinct role of macrophages in different
tumor microenvironments. Cancer Res 66, 605–612.
[10] Said N, Najwer I, and Motamed K (2007). Secreted protein acidic and rich in
cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor–
dependent survival signaling in ovarian cancer. Am J Pathol 170, 1054–1063.
[11] Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, and Patierno SR
(2000). Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell
invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60,
4629–4637.
[12] Symowicz J, Adley BP, Woo MMM, Auersperg N, Hudson LG, and Stack MS
(2005). Cyclooxygenase-2 functions as a downstream mediator of lysophospha-
tidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res
65, 2234–2242.
[13] Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y,
Boothby M, Joyce S, Carbone DP, et al. (2003). Cancer-associated immuno-
deficiency and dendritic cell abnormalities mediated by the prostaglandin EP2
receptor. J Clin Invest 111, 727–735.
[14] Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, and Fishman DA
(2004). Proinvasive properties of ovarian cancer ascites–derived membrane vesi-
cles. Cancer Res 64, 7045–7049.
[15] Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, Zage P, and Cohn
SL (2006). SPARC expression is associated with impaired tumor growth, in-
hibited angiogenesis and changes in the extracellular matrix. Int J Cancer 118,
310–316.
[16] Chlenski A, Guerrero LJ, Yang Q, Tian Y, Peddinti R, Salwen HR, and Cohn
SL (2007). SPARC enhances tumor stroma formation and prevents fibroblast
activation. Oncogene 26, 4513–4522.
[17] Haber CL, Gottifredi V, Llera AS, Salvatierra E, Prada F, Alonso L, Sage EH,
and Podhajcer OL (2007). SPARC modulates the proliferation of stromal but
not melanoma cells unless endogenous SPARC expression is downregulated.
Int J Cancer 122, 1465–1475.
[18] Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, and Podhajcer OL (1997). The
expression of the secreted protein acidic and rich in cysteine (SPARC) is asso-
ciated with the neoplastic progression of human melanoma. J Invest Dermatol
108, 210–214.
[19] Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS,
Andrade JA, Chilton-MacNeill S, Zielenska M, and Squire JA (2006). Effects of
THBS3, SPARC and SPP1 expression on biological behavior and survival in
patients with osteosarcoma. BMC Cancer 6, 237.
[20] Schultz C, Lemke N, Ge S, Golembieski WA, and Rempel SA (2002). Secreted
protein acidic and rich in cysteine promotes glioma invasion and delays tumor
growth in vivo. Cancer Res 62, 6270–6277.
[21] Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH,
and Yang PC (2005). Tumor-associated macrophages: the double-edged sword
in cancer progression. J Clin Oncol 23, 953–964.
[22] Kato Y, Nagashima Y, Baba Y, Kawano T, Furukawa M, Kubota A, Yanoma S,
Imagawa-Ishiguro Y, Satake K, Taguchi T, et al. (2005). Expression of SPARC
in tongue carcinoma of stage II is associated with poor prognosis: an immuno-
histochemical study of 86 cases. Int J Mol Med 16, 263–268.
[23] Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, and Sage
EH (2003). Enhanced growth of tumors in SPARC null mice is associated with
changes in the ECM. J Clin Invest 111, 487–495.
[24] Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A,
and Cohn SL (2004). Association of epigenetic inactivation of RASSF1A with
poor outcome in human neuroblastoma. Clin Cancer Res 10, 8493–8500.
[25] Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH,
Hruban RH, and Goggins M (2003). SPARC/osteonectin is a frequent target for
aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-
stromal interactions. Oncogene 22, 5021–5030.
Neoplasia Vol. 10, No. 10, 2008 SPARC Ameliorates Ovarian Cancer–Associated Inflammation Said et al. 1103
[26] Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana
UG, Iizasa T, Fujisawa T, Hiroshima K, and Gazdar AF (2005). Aberrant
methylation of SPARC in human lung cancers. Br J Cancer 92, 942–948.
[27] Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, and Kiviat N
(2006). Discovery of novel methylation biomarkers in cervical carcinoma by
global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev
15, 114–123.
[28] Rodriguez-Jimenez FJ, Caldes T, Iniesta P, Vidart JA, Garcia-Asenjo JL, and
Benito M (2007). Overexpression of SPARC protein contrasts with its transcrip-
tional silencing by aberrant hypermethylation of SPARC CpG-rich region in
endometrial carcinoma. Oncol Rep 17, 1301–1307.
[29] Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi MR, and Colombo MP
(2003). Leukocyte, rather than tumor-produced SPARC, determines stroma
and collagen type IV deposition in mammary carcinoma. J Exp Med 198,
1475–1485.
[30] Said N and Motamed K (2005). Absence of host-secreted protein acidic and rich
in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol
167, 1739–1752.
[31] Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, and Mok SC
(2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis
in ovarian cancer cells. Am J Pathol 159, 609–622.
[32] Mok SC, Chan WY, Wong KK, Muto MG, and Berkowitz RS (1996). SPARC,
an extracellular matrix protein with tumor-suppressing activity in human ovar-
ian epithelial cells. Oncogene 12, 1895–1901.
[33] Kato Y, Lewalle JM, Baba Y, Tsukuda M, Sakai N, Baba M, Kobayashi K,
Koshika S, Nagashima Y, Frankenne F, et al. (2001). Induction of SPARC by
VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 287,
422–426.
[34] Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, and Motamed K
(2007). Normalization of the ovarian cancer microenvironment by SPARC.
Mol Cancer Res 5, 1015–1030.
[35] Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F,
Pukrop T, Binder C, and Balkwill FR (2005). Macrophages induce invasiveness
of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175, 1197–1205.
[36] Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K,
Gordon S, and Balkwill FR (2006). Ovarian cancer cells polarize macrophages
toward a tumor-associated phenotype. J Immunol 176, 5023–5032.
[37] Mestdagt M, Polette M, Buttice G, Noel A, Ueda A, Foidart JM, and Gilles C
(2006). Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human
breast cancer cells. Int J Cancer 118, 35–42.
[38] Ghilardi G, Biondi ML, La Torre A, Battaglioli L, and Scorza R (2005). Breast
cancer progression and host polymorphisms in the chemokine system: role of
the macrophage chemoattractant protein-1 (MCP-1) −2518 G allele. Clin Chem
51, 452–455.
[39] Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C,
Calori G, Pessi F, Sperti C, et al. (2003). The CC chemokine MCP-1/CCL2
in pancreatic cancer progression: regulation of expression and potential mechan-
isms of antimalignant activity. Cancer Res 63, 7451–7461.
[40] Kuroda T, Kitadai Y, Tanaka S, Yang X, Mukaida N, Yoshihara M, and
Chayama K (2005). Monocyte chemoattractant protein-1 transfection induces
angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macro-
phage recruitment. Clin Cancer Res 11, 7629–7636.
[41] Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P,
Hu W, Savary CA, Kobayashi R, Freedman RS, et al. (2005). Peritoneal and
subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin
Cancer Res 11, 113–122.
[42] Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N,
Husseinzadeh N, McFarland-Mancini MM, and Drew AF (2007). Macro-
phages mediate inflammation-enhanced metastasis of ovarian tumors in mice.
Cancer Res 67, 5708–5716.
[43] Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, and Binder C
(2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation
with macrophages is due to TNF-alpha dependent up-regulation of matrix
metalloproteases. Carcinogenesis 25, 1543–1549.
[44] Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok
S, and Baker MS (2002). Overexpression of alpha(v)beta6 integrin in serous
epithelial ovarian cancer regulates extracellular matrix degradation via the plas-
minogen activation cascade. Carcinogenesis 23, 237–244.
[45] Belli R, Amerio P, Brunetti L, Orlando G, Toto P, Proietto G, Vacca M, and
Tulli A (2005). Elevated 8-isoprostane levels in basal cell carcinoma and in UVA
irradiated skin. Int J Immunopathol Pharmacol 18, 497–502.
[46] Rask K, Zhu Y, Wang W, Hedin L, and Sundfeldt K (2006). Ovarian epithelial
cancer: a role for PGE2-synthesis and signalling in malignant transformation
and progression. Mol Cancer 5, 62.
[47] Spinella F, Rosano L, Di Castro V, Natali PG, and Bagnato A (2004). Endothelin-
1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial
growth factor production and ovarian carcinoma cell invasion. J Biol Chem
279, 46700–46705.
[48] Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP, and
Saed GM (2002). Effects of prostaglandin E(2) on proliferation and apoptosis of
epithelial ovarian cancer cells. J Soc Gynecol Investig 9, 168–173.
[49] Fukuda R, Kelly B, and Semenza GL (2003). Vascular endothelial growth factor
gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by
hypoxia-inducible factor 1. Cancer Res 63, 2330–2334.
[50] Kiessling R, Kono K, Petersson M, and Wasserman K (1996). Immunosup-
pression in human tumor-host interaction: role of cytokines and alterations in
signal-transducing molecules. Springer Semin Immunopathol 18, 227–242.
[51] Lin MT, Juan CY, Chang KJ, Chen WJ, and Kuo ML (2001). IL-6 inhibits
apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells
through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 22, 1947–1953.
[52] Mantovani A, Schioppa T, Porta C, Allavena P, and Sica A (2006). Role of
tumor-associated macrophages in tumor progression and invasion. Cancer
Metastasis Rev 25, 315–322.
[53] Blackwell TS, Christman JW, Hagan T, Price P, Edens T, Morris PE, Wolff SN,
Goodman SA, and Christman BW (2000). Oxidative stress and NF-kappaB
activation: correlation in patients following allogeneic bone marrow transplan-
tation. Antioxid Redox Signal 2, 93–102.
[54] Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M, and Terao T
(2004). Upregulation of bikunin in tumor-infiltrating macrophages as a factor
of favorable prognosis in ovarian cancer. Gynecol Oncol 94, 725–734.
[55] Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, and Fidler
IJ (2002). Contributions of stromal metalloproteinase-9 to angiogenesis and
growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94, 1134–1142.
[56] Pace E, Siena L, Ferraro M, Profita M, Mondello P, Chiappara G, Montalbano
AM, Giarratano A, Bonsignore G, and Gjomarkaj M (2006). Role of prosta-
glandin E2 in the invasiveness, growth and protection of cancer cells in malig-
nant pleuritis. Eur J Cancer 42, 2382–2389.
[57] Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang
Q, Salwen HR, Farrer R, Bray J, et al. (2002). SPARC is a key Schwannian-
derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 62,
7357–7363.
[58] Taghizadeh F, Tang MJ, and Tai IT (2007). Synergism between vitamin D and
secreted protein acidic and rich in cysteine-induced apoptosis and growth in-
hibition results in increased susceptibility of therapy-resistant colorectal cancer
cells to chemotherapy. Mol Cancer Ther 6, 309–317.
[59] Hess LM and Alberts DS (2007). The role of intraperitoneal therapy in ad-
vanced ovarian cancer. Oncology (Williston Park) 21, 227–232 [discussion
232, 235, 239–242].
[60] Munoz-Casares FC, Rufian S, Rubio MJ, Lizarraga E, Diaz-Iglesias C, Aranda
E, Ciria R, Muntane J, Barrios P, Torres-Melero J, et al. (2007). Treatment of
peritoneal carcinomatosis from ovarian cancer. Present, future directions and
proposals. Clin Transl Oncol 9, 652–662.
[61] Kavanagh JJ (2007). Intraperitoneal chemotherapy in the treatment of ovarian
cancer. J Surg Oncol 96, 541–542.
1104 SPARC Ameliorates Ovarian Cancer–Associated Inflammation Said et al. Neoplasia Vol. 10, No. 10, 2008
